These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37499520)

  • 21. Mapping of genomic EGFRvIII deletions in glioblastoma: insight into rearrangement mechanisms and biomarker development.
    Koga T; Li B; Figueroa JM; Ren B; Chen CC; Carter BS; Furnari FB
    Neuro Oncol; 2018 Sep; 20(10):1310-1320. PubMed ID: 29660021
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates.
    Kastenhuber ER; Huse JT; Berman SH; Pedraza A; Zhang J; Suehara Y; Viale A; Cavatore M; Heguy A; Szerlip N; Ladanyi M; Brennan CW
    Acta Neuropathol; 2014 May; 127(5):747-59. PubMed ID: 24292886
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exosomes as a biomarker platform for detecting epidermal growth factor receptor-positive high-grade gliomas.
    Manda SV; Kataria Y; Tatireddy BR; Ramakrishnan B; Ratnam BG; Lath R; Ranjan A; Ray A
    J Neurosurg; 2018 Apr; 128(4):1091-1101. PubMed ID: 28574310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens.
    Feldkamp MM; Lala P; Lau N; Roncari L; Guha A
    Neurosurgery; 1999 Dec; 45(6):1442-53. PubMed ID: 10598712
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The epidermal growth factor receptor variant type III mutation frequently found in gliomas induces astrogenesis in human cerebral organoids.
    Kim HM; Lee SH; Lim J; Yoo J; Hwang DY
    Cell Prolif; 2021 Feb; 54(2):e12965. PubMed ID: 33283409
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New pattern of EGFR amplification in glioblastoma and the relationship of gene copy number with gene expression profile.
    Lopez-Gines C; Gil-Benso R; Ferrer-Luna R; Benito R; Serna E; Gonzalez-Darder J; Quilis V; Monleon D; Celda B; Cerdá-Nicolas M
    Mod Pathol; 2010 Jun; 23(6):856-65. PubMed ID: 20305620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.
    Sepúlveda-Sánchez JM; Vaz MÁ; Balañá C; Gil-Gil M; Reynés G; Gallego Ó; Martínez-García M; Vicente E; Quindós M; Luque R; Ramos A; Ruano Y; Pérez-Segura P; Benavides M; Sánchez-Gómez P; Hernández-Laín A
    Neuro Oncol; 2017 Oct; 19(11):1522-1531. PubMed ID: 28575464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Defining EGFR amplification status for clinical trial inclusion.
    French PJ; Eoli M; Sepulveda JM; de Heer I; Kros JM; Walenkamp A; Frenel JS; Franceschi E; Clement PM; Weller M; Ansell P; Looman J; Bain E; Morfouace M; Gorlia T; van den Bent M
    Neuro Oncol; 2019 Oct; 21(10):1263-1272. PubMed ID: 31125418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of epidermal growth factor receptor amplification and EGFRvIII in glioblastoma: meta-analysis.
    Chen JR; Xu HZ; Yao Y; Qin ZY
    Acta Neurol Scand; 2015 Nov; 132(5):310-22. PubMed ID: 25846813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas.
    Biernat W; Huang H; Yokoo H; Kleihues P; Ohgaki H
    Brain Pathol; 2004 Apr; 14(2):131-6. PubMed ID: 15193025
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Depatuxizumab Mafodotin (ABT-414)-induced Glioblastoma Cell Death Requires EGFR Overexpression, but not EGFR
    von Achenbach C; Silginer M; Blot V; Weiss WA; Weller M
    Mol Cancer Ther; 2020 Jun; 19(6):1328-1339. PubMed ID: 32371586
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beyond sequence variation: assessment of copy number variation in adult glioblastoma through targeted tumor somatic profiling.
    McNulty SN; Cottrell CE; Vigh-Conrad KA; Carter JH; Heusel JW; Ansstas G; Dahiya S
    Hum Pathol; 2019 Apr; 86():170-181. PubMed ID: 30594748
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glioblastomas harboring gene fusions detected by next-generation sequencing.
    Woo HY; Na K; Yoo J; Chang JH; Park YN; Shim HS; Kim SH
    Brain Tumor Pathol; 2020 Oct; 37(4):136-144. PubMed ID: 32761533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Robust detection of EGFR copy number changes and EGFR variant III: technical aspects and relevance for glioma diagnostics.
    Jeuken J; Sijben A; Alenda C; Rijntjes J; Dekkers M; Boots-Sprenger S; McLendon R; Wesseling P
    Brain Pathol; 2009 Oct; 19(4):661-71. PubMed ID: 19744038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monocentric evaluation of Ki-67 labeling index in combination with a modified RPA score as a prognostic factor for survival in IDH-wildtype glioblastoma patients treated with radiochemotherapy.
    Dumke R; Dumke C; Eberle F; Nimsky C; Keber U; Engenhart-Cabillic R; Lautenschläger S
    Strahlenther Onkol; 2022 Oct; 198(10):892-906. PubMed ID: 35612598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma.
    Stichel D; Ebrahimi A; Reuss D; Schrimpf D; Ono T; Shirahata M; Reifenberger G; Weller M; Hänggi D; Wick W; Herold-Mende C; Westphal M; Brandner S; Pfister SM; Capper D; Sahm F; von Deimling A
    Acta Neuropathol; 2018 Nov; 136(5):793-803. PubMed ID: 30187121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma.
    Aghi M; Gaviani P; Henson JW; Batchelor TT; Louis DN; Barker FG
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8600-5. PubMed ID: 16361543
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thyroid receptor-interacting protein 13 and EGFR form a feedforward loop promoting glioblastoma growth.
    Hu L; Shen D; Liang D; Shi J; Song C; Jiang K; Menglin Ren ; Du S; Cheng W; Ma J; Li S; Bi X; Barr MP; Fang Z; Xu Q; Li W; Piao H; Meng S
    Cancer Lett; 2020 Nov; 493():156-166. PubMed ID: 32860853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in Targeting the Epidermal Growth Factor Receptor Pathway by Synthetic Products and Its Regulation by Epigenetic Modulators As a Therapy for Glioblastoma.
    Nadeem Abbas M; Kausar S; Wang F; Zhao Y; Cui H
    Cells; 2019 Apr; 8(4):. PubMed ID: 31013819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.